Results 201 to 210 of about 9,492,801 (363)

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

The Prospective Registration of Clinical Trial Protocols: When Is a Health-Related Intervention Study Not a 'Clinical Trial'? [PDF]

Nurs Rep
Bressington D, Suriyawong W, Pipatpiboon N, Gray R.   +3 more
europepmc   +1 more source

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

New England Journal of Medicine, 1993
M. Simoons, E. Topol, R. Califf, F. Werf, P. Armstrong, P. Aylward, G. Barbash, E. Bates, A. Betriu, J. Chesebro, J. Col, D. Bono, J. Gore, A. Guerci, J. Hampton   +14 more
semanticscholar   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Crossover trials

Tidsskrift for Den norske legeforening, 2022
openaire   +2 more sources

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.

American Journal of Epidemiology, 2016
M. Hernán, J. Robins
semanticscholar   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Experiences in dissemination of results of a community-based tuberculosis prevention trial in children. [PDF]

Trials
Purchase SE, Seddon JA, Zimri K, Klaas A, Duong T, Martinson NA, Patel F, Staples S, Viljoen L, Schaaf HS, Hesseling AC.   +10 more
europepmc   +1 more source

Editorial: Clinical trial design and development in neonatal and perinatal medicine

Frontiers in Pediatrics
Mohamed E. Abdel-Latif, Mohamed E. Abdel-Latif, Mohamed E. Abdel-Latif, Yogavijayan Kandasamy, Yogavijayan Kandasamy, Yogavijayan Kandasamy, Sabita Uthaya, Sabita Uthaya, Dirk Bassler, Dirk Bassler, Jonathan M. Davis, Jonathan M. Davis   +11 more
doaj   +1 more source

An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19

Swiss Medical Weekly, 2020
Katheron Intson, Sachin A. Kumar, Amy Botta, Rachael Neckels, Connie Leung, Ali Jawaid   +5 more
doaj   +1 more source